ExcellGene SA, a Swiss biotech service provider specializing in mammalian cell line development, has entered a strategic collaboration with Cytovance Biologics, a contract manufacturing organization (CDMO) based in the U.S. The partnership aims to advance large molecule biologics development and manufacture. The collaboration leverages Chinese Hamster Ovary (CHO) and Human Embryonic Kidney (HEK) cells for mammalian cell lines for recombinant protein production and biological research. ExcellGene's custom CHO and HEK cell lines can be used to optimize protein quality, quantity, development timelines, and scalability for biomanufacturing through custom engineering to the specific requirements of a protein. By combining these engineered cell lines with Cytovance's cGMP manufacturing expertise, the companies expect to deliver a higher yield range of up to 10 g/L.